BridgeBio Oncology Therapeutics, Inc.
For the period ended Aug 11, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 11, 2026 · Filed Aug 11, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Key Program Highlights and Updates
Key Program Highlights and Updates
BBO-8520: An orally bioavailable small molecule direct inhibitor targeting both the ON and OFF states of KRAS G12C.
Continued to enroll BBO-8520 plus pembrolizumab combination in patients with NSCLC carrying KRAS G12C mutation.
Initiated BBO-8520 plus BBO-10203 combination in patients with G12C NSCLC.
BBO-11818: An orally bioavailable small molecule pan-KRAS inhibitor that targets mutant KRAS in both the ON and OFF states.
Continued to enroll BBO-11818 monotherapy across multiple dose levels.
Initiated dosing of BBO-11818 in combination with cetuximab.
Subsequent to the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203.
Presented preclinical data at AACR highlighting the potency of BBO-11818 in KRAS G12D and KRAS G12V CDXmodels, potent combination effect with cetuximab or BBO-10203, and complete tumor regressions through adaptive immunity in combination with anti PD-1 antibodies.
BBO-10203: An orally bioavailable small molecule with a novel mechanism of action designed to block the physical interaction between RAS and PI3Kα, inhibiting RAS-driven PI3Kα-AKT signaling in tumors.
Continued to enroll HR+ BC, HER2+/HR- BC, and colorectal (CRC) combination cohorts.
Presented preclinical data at AACR showing that BBO-10203 demonstrated strong in vivo combination effect with HER2 inhibitors tucatinib or trastuzumab in HER2amp tumor models.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.